1. At a Glance – From Sleeping Shell to Pharma Thriller?
₹121 crore market cap.
₹60.9 share price.
Up 17.5% in 3 months.
Up 140% in one year.
Quarterly sales? ₹48.4 crore.
Quarterly PAT? ₹1.00 crore.
Quarter-on-quarter sales growth? 813%.
Quarter-on-quarter profit growth? 567%.
And yet… ROCE is 0.96%. ROE is 0.64%.
Ladies and gentlemen, welcome to the curious case of Novelix Pharmaceuticals — a company that changed its name, changed its promoters, changed its business, raised money through preferential allotments, approved ₹500 crore borrowing limits… and then posted a sudden revenue explosion.
Is this the birth of a bulk drug powerhouse? Or is this a corporate makeover with Instagram filters?
Grab popcorn. We’re opening the books.
2. Introduction – From Trimurthi to Novelix: The Corporate Reincarnation
Originally incorporated in 1994, this company wasn’t always Novelix Pharmaceuticals. In FY25, it changed its name from Trimurthi Limited to Novelix Pharmaceuticals Limited.
New name.
New promoters.
New business objectives.
New capital raises.
Basically, full Bollywood-style rebirth.
In FY25, Srinidhi Fine Chemicals LLP and others acquired the company through an open offer. Post-acquisition:
- Management changed
- Business diversified
- Preferential allotments happened
- Borrowing limits increased to ₹500 crore
- Investment/loan approval limit increased to ₹500 crore
That’s not evolution. That’s corporate gym transformation.
But here’s the fun part — despite all the noise, the actual numbers are tiny.
TTM sales: ₹128 crore
TTM PAT: ₹2 crore
For context, some mid-sized pharma companies sneeze more revenue than this.
So the big question is:
Are we looking at the early innings of something big?
Or is this a classic “story first, margins later” play?
Let’s dissect.
3. Business Model – WTF Do They Even Do?
Currently, Novelix operates in:
- Pharmaceutical research
- Production and trading of bulk drugs (APIs)
- Key starting materials and intermediates
- Healthcare research, analytics, and technology
Revenue breakup FY25:
- Pharmaceuticals: 96%
- Sale of shares: 4%
Translation: They primarily trade pharmaceuticals.
Important word: Trading.
Trading bulk
